Other equities research analysts also recently issued reports about the company. ValuEngine raised GW Pharmaceuticals PLC- from a “sell” rating to a “hold” rating in a research report on Wednesday, September 4th. Needham & Company LLC initiated coverage on GW Pharmaceuticals PLC- in a research report on Monday, October 21st. They issued a “buy” rating and a $200.00 price target on the stock. Oppenheimer lowered their price target on GW Pharmaceuticals PLC- to $222.00 and set an “outperform” rating on the stock in a research report on Wednesday, November 6th. Morgan Stanley raised their price target on GW Pharmaceuticals PLC- to $238.00 and gave the company an “overweight” rating in a research report on Wednesday, August 7th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $174.00 price target on shares of GW Pharmaceuticals PLC- in a research report on Wednesday, November 6th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and fifteen have issued a buy rating to the company. GW Pharmaceuticals PLC- presently has an average rating of “Buy” and an average target price of $198.00.
Shares of NASDAQ:GWPH traded up $3.82 during midday trading on Friday, hitting $113.23. The company’s stock had a trading volume of 759,067 shares, compared to its average volume of 511,676. The stock has a market capitalization of $4.16 billion, a price-to-earnings ratio of -10.72 and a beta of 2.28. The stock’s 50 day simple moving average is $122.70 and its 200 day simple moving average is $154.23. GW Pharmaceuticals PLC- has a fifty-two week low of $90.14 and a fifty-two week high of $196.00. The company has a debt-to-equity ratio of 0.03, a quick ratio of 7.59 and a current ratio of 8.31.
In related news, insider Douglas B. Snyder sold 5,424 shares of the stock in a transaction dated Monday, August 19th. The shares were sold at an average price of $13.04, for a total value of $70,728.96. Following the completion of the sale, the insider now owns 73,740 shares in the company, valued at $961,569.60. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 3.60% of the stock is currently owned by company insiders.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Kavar Capital Partners LLC bought a new stake in shares of GW Pharmaceuticals PLC- in the second quarter valued at about $26,000. Prestige Wealth Management Group LLC bought a new stake in shares of GW Pharmaceuticals PLC- in the second quarter valued at about $28,000. Pathstone Family Office LLC bought a new stake in shares of GW Pharmaceuticals PLC- in the second quarter valued at about $29,000. Redhawk Wealth Advisors Inc. bought a new stake in shares of GW Pharmaceuticals PLC- in the second quarter valued at about $34,000. Finally, Signaturefd LLC lifted its stake in shares of GW Pharmaceuticals PLC- by 192.5% in the third quarter. Signaturefd LLC now owns 234 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 154 shares during the period. Institutional investors and hedge funds own 82.89% of the company’s stock.
About GW Pharmaceuticals PLC-
GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. Its lead product is Epidiolex, an oral medicine for the treatment of refractory childhood epilepsies, as well as for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms.
Featured Story: What is Elliott Wave theory?
Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.